Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANP in African Americans With Hypertension
NCT04542681Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- May 2018
- Primary completion
- Dec 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of M-atrial natriuretic peptide in hypertension (HTN) (3 arms), sponsored by Mayo Clinic. Primary endpoint: Change in Blood Pressure at 12 hours. Planned start May 2018; status: withdrawn.
02
Drugs
M-atrial natriuretic peptide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04542681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542681.